Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Bullish +55

Is Becton, Dickinson and Company (BDX) A Good Stock To Buy Now?

AI-generated analysis

πŸ“ˆ Becton, Dickinson and Company (BDX) shares traded at $149.99 on June 8, 2026, with a forward P/E of 11.21.

πŸ’° Q2 fiscal 2026 continuing-operations revenue reached $4.714 billion with adjusted diluted EPS of $2.90.

πŸš€ Management raised full-year fiscal 2026 adjusted EPS guidance to a range of $12.52–$12.72.

πŸ’Έ The Waters transaction generated approximately $4.0 billion in net cash for the company.

πŸ”„ A $2.0 billion asset sale and repurchase (ASR) is being prioritized alongside ongoing buybacks.

πŸ“‰ Buyback authorization stands at approximately 4.2% of total shares outstanding.

πŸ₯ The business spans medical technology franchises in diagnostics, life sciences, and high-margin consumables.

πŸ“Š Analysts view the current valuation as disconnected from mid-single-digit growth and recurring revenues.

πŸ” The company is simplifying its reporting base to focus on continuing operations post-spin.

πŸ“ˆ Market multiples are expected to expand toward normalized levels if execution continues.

πŸ›‘οΈ Improved transparency and lower earnings volatility are cited as key drivers for future performance.

πŸ† BDX is described as a steady compounding medtech platform rather than a transition story.

Bullish Signals
  • BDX raised its fiscal 2026 adjusted EPS guidance to $12.52–$12.72, signaling strengthening execution across core segments.
  • The company generated approximately $4.0 billion in net cash from the Waters transaction, enabling significant capital return initiatives.
  • Management is executing a $2.0 billion asset sale and repurchase (ASR) combined with ongoing buybacks of ~4.2% of shares outstanding.
  • The stock trades at a forward P/E of 11.21, which analysts argue is disconnected from the company's durable recurring revenue streams and growth potential.
  • Continuing-operations revenue in Q2 fiscal 2026 reached $4.714 billion with adjusted diluted EPS of $2.90.
Full Analysis
The article presents a bullish investment thesis on Becton, Dickinson and Company (BDX), arguing that the stock is currently mispriced following its strategic transformation. As of June 8, 2026, shares traded at $149.99 with a forward P/E of 11.21, which analysts suggest is disconnected from the company's mid-single-digit growth potential and recurring revenue streams. In Q2 fiscal 2026, BDX reported continuing-operations revenue of $4.714 billion and adjusted diluted EPS of $2.90. The company raised its full-year adjusted EPS guidance to a range of $12.52–$12.72, signaling improved execution across core segments like diagnostics and life sciences. Following the Waters transaction, which generated approximately $4.0 billion in net cash, management is prioritizing capital return through a $2.0 billion asset sale and repurchase (ASR) and an ongoing buyback authorization of roughly 4.2% of shares outstanding. The company is simplifying its reporting to focus on continuing operations, reducing noise from separation and restructuring charges. The thesis concludes that BDX resembles a steady compounding medtech platform rather than a transition story, with upside driven by capital returns and potential multiple expansion toward normalized medtech multiples as earnings quality improves and volatility decreases.